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Abstract
Aberrant telomere length measured in blood has been associated with increased risk of several cancer types. In the field of
hereditary non-polyposis colorectal cancer (CRC), and more particularly in Lynch syndrome, caused by germline mutations
in the mismatch repair (MMR) genes, we recently found that cancer-affected MMR gene mutation carriers had shorter
telomeres and more pronounced shortening of telomere length with age than controls and unaffected MMR gene mutation
carriers. Here we evaluate blood telomere length in MMR-proficient hereditary non-polyposis CRC, i.e. familial CRC type X
(fCRC-X). A total of 57 cancer-affected and 57 cancer-free individuals from 34 Amsterdam-positive fCRC-X families were
analyzed and compared to the data previously published on 144 cancer-affected and 100 cancer-free MMR gene mutation
carriers, and 234 controls. Relative telomere length was measured using a monochrome multiplex quantitative PCR method,
following strict measures to avoid sources of bias and adjusting by age. Despite the retrospective nature of our study, the
results show that longer telomeres associate with cancer risk in fCRC-X, thus identifying different patterns of telomere
length according to the status of the MMR system.
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Introduction
Family history is one of the strongest risk factors for the
development of colorectal cancer (CRC) and is involved in
approximately 20% of all CRC cases. However, only 2–6% of all
CRCs are explained by germline mutations in known high-
penetrance CRC genes. The Amsterdam criteria were defined to
identify hereditary non-polyposis CRC cases, considering young
age (,50 years) at cancer diagnosis and high familial aggregation
of CRC (Amsterdam I) or other related tumors (Amsterdam II).
Approximately 60% of the families that fulfill the Amsterdam
criteria show DNA mismatch repair (MMR) deficiency as a
consequence of a germline mutation or epimutation in a MMR
gene, i.e. MLH1, MSH2, MSH6 or PMS2 (Lynch syndrome; LS).
The remaining 40% do not show MMR defects and the genetic
cause of the familial CRC aggregation is still unknown, having
been grouped as familial CRC type X (fCRC-X) [1,2].
Chromosome telomeres consist of multiple short repeats
(TTTAGG) that protect against large-scale genomic rearrange-
ments. Telomeres shorten with cell division, eventually leading to
cellular senescence. On rare occasions, cells that aberrantly bypass
replicative senescence with critically short telomeres may develop
genomic instability and potentially become tumorigenic. In cancer
cells, however, as in stem cells, telomerase, the enzyme that adds
telomeric repeats to the chromosome ends, is expressed, compen-
sating for telomere erosion and preventing senescence/apoptosis
[3–5].
Germline mutations in the components of the telomerase
complex cause dyskeratosis congenita. Patients with this disorder
have short telomeres, which lead to bone marrow failure and
increased cancer risk [6]. Likewise, mouse models with telomerase
deficiency and short telomeres have high risk of cancer [7]. Recent
epidemiological studies have evaluated telomere length measured
in peripheral blood DNA as a potential biomarker of cancer risk.
Several studies have reported associations between telomere length
and cancer risk, although the data are inconsistent among studies
and tumor types [8]. In CRC studies, contradictory results have
been observed, apparently due to differences in study population,
study design, analytical approach, sample size, or exposure to
environmental factors [9–15].
Regarding hereditary CRC, our group recently reported that
cancer-affected MMR gene mutation carriers had shorter
telomeres and showed faster telomere attrition with age, measured
in blood, than controls and cancer-free MMR gene mutation
carriers [16]. Nevertheless, the role of telomere length as cancer
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risk modifier in LS could not be asserted since it had been argued
that the shortened telomeres observed in retrospectively collected
samples from cancer-affected individuals might be a consequence
of the disease [8,14]. However, the fact that cancer-free mutation
carriers had longer telomeres than cancer-free controls provided
additional evidence in support to the hypothesis that telomere
length might act as a cancer risk modifier in LS [16].
Here we report the first study of the behavior of blood telomere
length in MMR-proficient hereditary non-polyposis CRC, i.e.
fCRC-X, and compare it to the behavior observed in controls and




Written informed consent was obtained from all subjects. The
study was approved by the Ethics Committee of IDIBELL (ref.
PR221/09).
Study Participants
A total of 114 individuals, 57 cancer-affected and 57 cancer-
free, from 34 fCRC-X families were included in the study. These
families fulfilled the Amsterdam criteria but did not show MMR
defects (microsatellite instability or loss of expression of the MMR
proteins MLH1, MSH2, MSH6 and PMS2). In all, 76.5% (26/34)
of the families fulfilled Amsterdam I criteria and 23.5% (8/34)
Amsterdam II. For comparative purposes, previously published
telomere length data from individuals belonging to LS families and
from controls were included in the analyses [16]. Familial CRC-X,
LS and control samples were all of Caucasian origin and recruited
from the same homogeneous population (the Spanish region of
Catalonia) through the Hereditary Cancer Program of the Catalan
Institute of Oncology, IDIBELL. Table 1 shows the characteristics
of the fCRC-X cases studied, comparing them to the LS
individuals and controls previously analyzed [16].
Relative Telomere Length Measurement
Relative telomere length (RTL) was assessed using a mono-
chrome multiplex quantitative PCR method [17], under the same
conditions as in Segui et al. [16]. Moreover, MMR-proficient
hereditary cases were run together with LS cases and controls. In
order to rule out artifacts or technical sources of variation, a
standard curve was included in each run (384-well plate), each
sample was assayed in triplicate, and whenever possible, equal
numbers of samples from different clinical groups were run in the
same plate. Storage and DNA extraction from peripheral blood
were performed at the same facility and using the same extraction
methods, as recommended for retrospective telomere length
studies [8].
Statistical Analyses
RTL was adjusted by age based on the telomere length
shortening occurring with age in the general population (controls),
as previously reported [16,18]. Differences in age-adjusted
telomere lengths were analyzed using the Wilcoxon rank sum test
(Mann-Whitney U). The Kruskal-Wallis rank sum test was used to
compare the demographic characteristics among groups. All tests
were two-sided and p-values below 0.05 were considered
statistically significant. The analyses were performed using R
statistical software.
Results
Age-adjusted RTL was evaluated in 57 cancer-affected fCRC-X
patients and 57 unaffected individuals from 34 fCRC-X families.
The results were compared to the results we published in a
previous study of 144 cancer-affected MMR gene mutation
carriers, 100 unaffected MMR gene mutation carriers and 234
controls [16].
Cancer-affected fCRC-X cases showed significantly longer
telomeres than unaffected fCRC-X individuals (p = 0.009) and
cancer-free controls (p = 0.013) (Fig. 1). These results were in sharp
contrast to those previously observed in LS, where telomere
lengths detected in cancer-affected MMR gene mutation carriers
were shorter than those in unaffected mutation carriers (p = 0.032)
[16]. On the other hand, cancer-free fCRC-X cases showed
shorter telomeres than cancer-free MMR gene mutation carriers
(p = 0.015), but of similar length to controls (Fig. 1).
Discussion
We found that longer telomeres are associated with cancer in
fCRC-X. Moreover, based on data previously published by our
Table 1. Characteristics of the hereditary non-polyposis CRC and control groups studied. Data on Lynch syndrome families and
controls were published previously [16].
fCRC-X families (n=34)
Lynch syndrome families (n =96) MMR
gene mutation carriers 2Controls 3P-value
1Cancer Cancer-free 1Cancer Cancer-free
N 57 57 144 100 234
Median age at blood draw
(6 SD)
56.0 (613.9) 50.0 (620.3) 51.5 (613.4) 35.0 (611.5) 42.0 (614.9) 0.037
Sex: n (%) M: 27 (47.4) M: 28 (49.1) M: 74 (51.4) M: 40 (40.0) M: 92 (39.3) 0.968
F: 30 (52.6) F: 29 (50.9) F: 70 (48.6) F: 60 (60.0) F: 142 (60.7)
Median age at cancer
diagnosis (6 SD)
49.0 (613.4) – 43.0 (612.9) – – 0.278
N, number of subjects; SD, standard deviation; M, male; F, female.
1Cancer: Individuals affected with a LS-associated cancer: CRC and/or cancer of the endometrium, ovary, stomach, small bowel, hepatobiliary tract, pancreas, upper uro-
epithelial tract or brain.
2Controls include non-carriers from LS families (n = 144) and unrelated cancer-free controls (n = 90).
3Kruskal-Wallis rank sum test.
doi:10.1371/journal.pone.0086063.t001
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group [16], MMR-deficient and -proficient non-polyposis hered-
itary cases show distinct patterns of blood telomere length,
suggesting that the status of the MMR system is key in defining
telomere length in hereditary cases.
Several epidemiological studies have investigated the association
of telomere length with CRC risk in the general population,
producing conflicting results [19]. Evidence from retrospective
studies indicates that telomeres in peripheral blood cells are
shorter in CRC cases than controls. However, this association has
not been replicated in prospective studies, suggesting that the
association between short telomeres and CRC in retrospective
studies is somehow the result of disease, treatment or differential
survival rather than the cause (effect of reverse causation) [14].
Regarding prospective studies, no association was found in three
relatively small studies (134–191 cases vs. 306–406 controls) [9–
11]. However, more recently, larger prospective studies found that
longer telomeres were associated with higher CRC risk (cases/
controls = 2,157/3,921) [14], or that both long and short telomeres
increased CRC risk (cases/controls = 441/549) [15].
Despite the retrospective nature of our study, we found that
cancer-affected fCRC-X individuals had longer telomeres than
cancer-free members of the same type X families, controls, and
cancer-affected members of LS families (MMR gene mutation
carriers). Therefore, longer telomeres are associated with cancer
risk in MMR-proficient hereditary non-polyposis CRC, as
observed in large prospective population-based CRC series
[14,15]. Further studies assessing telomere length before and after
cancer diagnosis in fCRC-X cases will be crucial to demonstrate
the precise effect of cancer on blood telomere length in this group
of patients.
Previous evidence supports the hypothesis that long telomeres
might increase cancer risk: first, long telomeres may delay cellular
Figure 1. Age-adjusted RTL in subjects belonging to fCRC-X and LS families. The different groups correspond to: cancer-affected fCRC-X
cases (median age-adjusted RTL: 0.017); cancer-free individuals from fCRC-X families (median: 20.215); cancer-affected MMR gene mutation carriers
(median: 20.131); cancer-free MMR gene mutation carriers (median: 20.079); and cancer-free controls (median: 20.092). Differences in age-adjusted
RTL were analyzed using the Wilcoxon rank sum test (Mann-Whitney U). The boxes represent the interquartile range of distributions (25th and 75th
percentiles); the horizontal lines within the boxes, the medians; and the vertical lines, the 5th and 95th percentiles. Data from LS families and controls
were published previously [16].
doi:10.1371/journal.pone.0086063.g001
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senescence and apoptosis, increasing the chance that genetic
abnormalities will accumulate [5,20]; secondly, a subset of
colorectal tumors has longer telomeres than the adjacent non-
tumor colon mucosa [21]. Telomere length assessment in fCRC-X
tumors will provide additional insight into whether MMR-
proficient hereditary tumors also have elongated telomeres.
Similarly, knowing the levels of telomerase expression or of
enzymatic activity in peripheral blood and tumor samples might
aid the design of specific therapeutic and/or preventive approach-
es for fCRC-X patients in the future [22].
Our findings, together with those observed in large population-
based CRC series [14,15], suggest that longer telomeres are a risk
factor for hereditary and sporadic MMR-proficient CRC.
Following this observation, it is plausible to hypothesize that
longer telomeres also act as modifiers of the age of onset of cancer
and/or polyposis in other MMR-proficient CRC syndromes.
In conclusion, in contrast to in the observations for LS but in
line with the results of large CRC prospective studies, elongated
telomeres are associated with increased cancer risk in Amsterdam-
positive MMR-proficient hereditary non-polyposis CRC.
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